Blood markers asprosin and microRNA in young women with metabolic syndrome
Studies blood markers in young women with and without metabolic syndrome.
Plain-language title generated from the registry record
Registry title: Asprosin and miRNA Expression in Young Women With Metabolic Syndrome
Key facts
- Where
- Nowy Targ, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 35 years old?
Source: NCT07917364, who can take part
Where in Poland
- Institute of Medicine, University of Applied Sciences in Nowy Targ, Kokoszków 71, 34-400 Nowy Targ, PolandNowy Targ, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Applied Sciences in Nowy Targ
- Trial code
- NCT07917364
- Record updated
- 4 November 2026
- Original description
Metabolic syndrome is a major risk factor for cardiovascular disease and type 2 diabetes, and its prevalence in young adults is increasing. Early identification of individuals at risk may improve prevention strategies. This observational, cross-sectional case-control study investigates the relationship between serum asprosin concentration, the expression of six selected circulating microRNAs, and the components and risk factors of metabolic syndrome in young women aged 18 to 35 years. Two equally sized groups will be compared: women meeting NCEP ATP III criteria for metabolic syndrome and healthy age-matched controls. Participants attend a single study visit during which fasting blood samples, anthropometric and body composition measurements, blood pressure, and validated questionnaires assessing physical activity, diet, sleep quality, perceived stress, and quality of life are collected. The study aims to determine whether asprosin and the selected microRNA profile have diagnostic value as biomarkers of metabolic syndrome in this population.Read full original descriptionShow less
Association Between Serum Asprosin Concentration and Expression of Selected miRNAs With Risk Factors and Components of Metabolic Syndrome in Young Women: Diagnostic Perspectives
Metabolic syndrome is a major risk factor for cardiovascular disease and type 2 diabetes, and its prevalence in young adults is increasing. Early identification of individuals at risk may improve prevention strategies. This observational, cross-sectional case-control study investigates the relationship between serum asprosin concentration, the expression of six selected circulating microRNAs, and the components and risk factors of metabolic syndrome in young women aged 18 to 35 years. Two equally sized groups will be compared: women meeting NCEP ATP III criteria for metabolic syndrome and healthy age-matched controls. Participants attend a single study visit during which fasting blood samples, anthropometric and body composition measurements, blood pressure, and validated questionnaires assessing physical activity, diet, sleep quality, perceived stress, and quality of life are collected. The study aims to determine whether asprosin and the selected microRNA profile have diagnostic value as biomarkers of metabolic syndrome in this population.
Inclusion: Female sex; Age 18 to 35 years; Regular menstrual cycle; Not engaged in competitive sports training in any discipline; Non-smoker; No alcohol abuse; No continuous pharmacotherapy, with the exception of treatment for diabetes and/or antihypertensive treatment; no use of hormonal contraception; Written informed consent for study participation and processing of personal data.
Exclusion: Continuous pharmacotherapy for indications other than diabetes and/or hypertension, including any form of hormonal contraception (oral, transdermal, vaginal, implant, injectable or intrauterine); Age outside the range of 18 to 35 years; Irregular menstrual cycle; Pregnancy or breastfeeding; Competitive sports training in any discipline; Current smoking; Alcohol abuse; Lack of written informed consent for study participation and processing of personal data.